All Bristol-Myers Squibb articles
-
BusinessPfizer backs protein degrader drugs with Arvinas deal
$1bn investment to commercialise breast cancer treatment
-
BusinessBMS and Eisai agree antibody-drug conjugate commercialisation deal
Companies will jointly develop cancer treatment, with BMS paying up to $3 billion for shared rights
-
ResearchBaran and Blackmond team up to wave farewell to tough ether syntheses
Oxidative decarboxylation produces carbocations that greatly speed up hindered ether production
-
ResearchLigand selector steers C–N cross-couplings down most sustainable path
Tool is step towards strategy that considers reagents and reactants above and below the arrow
-
BusinessBristol-Myers Squibb to buy Celgene for $74 billion
Deal boosts BMS’s cancer and immunology pipeline with 5 drugs in late stage clinical trials
-
BusinessNovartis exit from antibiotics a setback for race against resistance
Experts say business models must change to halt big pharma exodus
-
BusinessBMS stimulates cancer drug hopes with giant collaboration
Immunooncology pioneer will pay up to $3.6bn in hope Nektar drug will help non-responders
-
BusinessUS to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
BusinessLong road to recovery for Puerto Rico pharmaceuticals
As inhabitants begin to rebuild their lives after the devastation of hurricane Maria, the island’s drug manufacturers are recovering slowly
-
BusinessBristol-Myers Squibb bags immunotherapy unicorn
Deal will add to pharma giant’s cancer portfolio
-
BusinessChina approves BMS’s hepatitis C drugs
Combination is first all-oral treatment in China, where Gilead’s Sovaldi is not yet approved
-
BusinessMerck & Co settles cancer antibody patent dispute
US firm will pay Bristol-Myers Squibb and Ono $625m plus royalties on future sales of immunotherapy
-
BusinessBristol-Myers Squibb planning huge reorganisation in the US
Job losses likely as Hopewell, New Jersey site will close by 2020
-
BusinessAmgen and Advaxis partner on immuno-oncology
Deal covers rights to system for building cancer therapies specific to a patient’s own tumours
-
BusinessCelgene and Jounce team up against cancer
Firms promise next-generation immuno-oncology as existing drugs rack up successes
-
Business
GSK’s ViiV to buy HIV drugs from BMS
Deal hands over Bristol-Myers Squibb’s entire HIV pipeline as the company looks to quit virology research
-
Business
Bristol-Myers Squibb to buy Cardioxyl for heart drug
Deal worth up to $2bn gives BMS full rights to Phase II clinical candidate
-
Business
BMS agrees $1.7bn immuno-oncology collaboration
Deal strengthens cancer antibody alliance with Five Prime Therapeutics
-
Business
Bristol-Myers Squibb fined for alleged Chinese bribes
US Securities and Exchange Commission accepts $14m settlement for charges covering the last five years
-
FeaturePharma queues up for checkpoint inhibitor collaborations
Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits